Literature DB >> 10714021

Surgical management of pulmonary aspergilloma. Role of single-stage cavernostomy with muscle transposition.

N Ono1, K Sato, H Yokomise, K Tamura.   

Abstract

OBJECTIVE: We reviewed the outcome of the patients with aspergilloma who were treated surgically.
METHODS: Between July 1991 and October 1996, 11 patients with pulmonary aspergilloma underwent surgery. One underwent sequential bilateral tboracotomy and two underwent re-operation. The total number of operations was 14. Surgical procedures consisted of 5 cavernostomies with muscle transposition, 3 cavernostomies with muscle transposition and thoracoplasty, 1 lobectomy 1 pneumonectomy, 1 segmentectomy and 3 partial resections.
RESULTS: Morbidity and mortality rates were 28.6% and 7.1%, respectively Two patients who underwent cavernostomy and muscle transposition experienced a relapse of aspergilloma 19 and 29 months after the operation, respectively, but both successfully underwent re-operation, including cavernostomy. Both are free of symptoms 28 and 30 months after re-operation, respectively. All survivors except for one who died of multiple organ failure remain free of symptoms 14 to 60 months after the most recent operation.
CONCLUSION: Our experience was not a controlled trial and two relapsed cases had undergone cavernostomy, our series may suggest that single-stage cavernostomy with muscle transposition is a viable surgical option for patients with pulmonary aspergilloma.

Entities:  

Mesh:

Year:  2000        PMID: 10714021     DOI: 10.1007/bf03218085

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  15 in total

1.  Broncho-pulmonary aspergillosis; a review and a report of eight new cases.

Authors:  K F W HINSON; A J MOON; N S PLUMMER
Journal:  Thorax       Date:  1952-12       Impact factor: 9.139

2.  Pulmonary aspergilloma. Results of surgical treatment.

Authors:  R C Daly; P C Pairolero; J M Piehler; V F Trastek; W S Payne; P E Bernatz
Journal:  J Thorac Cardiovasc Surg       Date:  1986-12       Impact factor: 5.209

3.  Severe hemoptysis associated with pulmonary aspergilloma. Percutaneous intracavitary treatment.

Authors:  M J Shapiro; S M Albelda; R L Mayock; G K McLean
Journal:  Chest       Date:  1988-12       Impact factor: 9.410

4.  What happens to patients with pulmonary aspergilloma? Analysis of 23 cases.

Authors:  P Rafferty; B A Biggs; G K Crompton; I W Grant
Journal:  Thorax       Date:  1983-08       Impact factor: 9.139

5.  Surgical management of symptomatic pulmonary aspergilloma.

Authors:  J W Battaglini; G F Murray; B A Keagy; P J Starek; B R Wilcox
Journal:  Ann Thorac Surg       Date:  1985-06       Impact factor: 4.330

6.  Surgical treatment of pulmonary aspergilloma.

Authors:  H Soltanzadeh; A R Wychulis; F Sadr; P J Bolanowski; W E Neville
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

7.  Management of massive hemoptysis by bronchial artery embolization.

Authors:  R Uflacker; A Kaemmerer; C Neves; P D Picon
Journal:  Radiology       Date:  1983-03       Impact factor: 11.105

8.  Surgical treatment of pulmonary and pleuro-pulmonary Aspergillus disease.

Authors:  P Wex; E Utta; W Drozdz
Journal:  Thorac Cardiovasc Surg       Date:  1993-02       Impact factor: 1.827

9.  Hemoptysis and pulmonary aspergilloma: operative versus nonoperative treatment.

Authors:  S L Faulkner; R Vernon; P P Brown; R D Fisher; H W Bender
Journal:  Ann Thorac Surg       Date:  1978-05       Impact factor: 4.330

10.  Surgical treatment of pulmonary aspergilloma and Aspergillus empyema.

Authors:  T Shirakusa; H Ueda; T Saito; K Matsuba; J Kouno; N Hirota
Journal:  Ann Thorac Surg       Date:  1989-12       Impact factor: 4.330

View more
  1 in total

1.  [Severity Factors of Pulmonary Aspergilloma in the Surgical Intensive Care Unit of Joseph Ravoahangy Andrianavalona Hospital, Antananarivo, Madagascar].

Authors:  N N M Razafimanjato; J M Rakotoson; M Ravoatrarilandy; R L Andrianasolo; A T Rajaonera; N E Raveloson; H J L Rakotovao
Journal:  Med Trop Sante Int       Date:  2021-02-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.